|
November 13, 2025
|
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
|
|
|
November 3, 2025
|
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
|
|
|
September 29, 2025
|
Outlook Therapeutics Provides Update on Type A Meeting with FDA
|
|
|
September 3, 2025
|
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
|
|
|
September 2, 2025
|
Outlook Therapeutics Requests Type A Meeting with FDA
|
|
|
August 28, 2025
|
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
|
|
|
August 14, 2025
|
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
|
|
|
July 24, 2025
|
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
|
|
|
July 22, 2025
|
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
|
|
|
July 1, 2025
|
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
|
|